← Back to Search

Moisturizer

Natural Oil-Based Moisturizer for Eczema

N/A
Recruiting
Research Sponsored by Integrative Skin Science and Research
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinical diagnosis of active atopic dermatitis
vIGA-AD (validated Investigator Global Assessment-Atopic Dermatitis) score of 'mild' (2) or 'moderate' (3) at Baseline
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights

Study Summary

This trial will compare coconut & sunflower seed oil and oatmeal to see how they affect skin conditions in children aged 2-17.

Who is the study for?
This trial is for boys and girls aged 2-17 with active atopic dermatitis, as shown by certain scores on the EASI and vIGA-AD scales. It's not for those allergic to ingredients in the moisturizers being tested, have only hand/foot eczema, are pregnant, have a skin infection or need systemic therapy.Check my eligibility
What is being tested?
The study tests moisturizers made from coconut oil and sunflower seed oil derived isosorbide disesters plus colloidal oatmeal against a control moisturizer to see which helps pediatric atopic dermatitis more effectively.See study design
What are the potential side effects?
Potential side effects may include skin irritation or allergic reactions due to sensitivity to any of the components in the moisturizers such as coconut oil, sunflower seed oil or other ingredients.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with active atopic dermatitis.
Select...
My eczema is rated as mild or moderate.
Select...
I am between 2 and 17 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Eczema Area and Severity Index (EASI)
Itch
Shift in the Skin Microbiome
+3 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Experimental Topical ProductActive Control1 Intervention
Topical moisturizer With Colloidal Oatmeal and Isosorbide Diesters + Topical Steroids
Group II: Control Topical ProductPlacebo Group1 Intervention
Topical moisturizer With Colloidal Oatmeal WITHOUT Isosorbide Diesters + Topical Steroids

Find a Location

Who is running the clinical trial?

Integrative Skin Science and ResearchLead Sponsor
31 Previous Clinical Trials
2,692 Total Patients Enrolled
Sytheon Ltd.Industry Sponsor
6 Previous Clinical Trials
230 Total Patients Enrolled

Media Library

Control Moisturizer (Moisturizer) Clinical Trial Eligibility Overview. Trial Name: NCT05688735 — N/A
Atopic Dermatitis Research Study Groups: Experimental Topical Product, Control Topical Product
Atopic Dermatitis Clinical Trial 2023: Control Moisturizer Highlights & Side Effects. Trial Name: NCT05688735 — N/A
Control Moisturizer (Moisturizer) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05688735 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this experiment encompass participants aged 35 or older?

"Per the study's eligibility standards, those between 2 and 17 years old are able to apply. This particular trial features 97 entries for participants under 18 and 148 trials for adults 65+."

Answered by AI

Is enrollment for this research still possible?

"As illustrated on clinicaltrials.gov, this study is no longer accepting patients for enrolment. Initially posted on January 20th of 2023 and last amended 9 days later, the trial has since finished its recruitment period; however, there are currently 214 other trials recruiting right now."

Answered by AI

Am I eligible to take part in this research endeavor?

"This clinical trial is actively enrolling 40 children aged between 2 and 17 with atopic dermatitis. To be eligible, the patient must present a vIGA-AD score of "mild" or "moderate", an EASI index of 5 or above, and have been diagnosed with active atopic dermatitis by a doctor."

Answered by AI
~20 spots leftby Apr 2025